Prognostic factors affecting outcome of vascular growth factor inhibitor bevacizumab (Avastin) therapy and reactivation of the disease in the wet age related degeneration of the eye.

The effect of anterior chamber protein concentration, gene polymorphisms and complement factors on visual acuity, contrast sensitivity, microperimetry, optical coherence tomography (OCT) findings and need of repeated drug injections in patients with exudative age related macular degeneration treated with intravitreal bevacizumab (Avastin) injection therapy.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000223336

Enrollment

Registered

2008-04-28

Start date

2008-05-07

Completion date

2010-04-30

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of the study is to find factors that may affect the efficacy of the intraocular vascular growth factor inhibitor treatment in patients with the wet form of age related degeneration of the eye. Factors studied are specific genetic markers, proteins involved in immune response and protein concentration in the anterior chamber of the eye.

Interventions

Bevacizumab 25 mg/ml, Avastin, Roche, 0,05 ml, 1,25 mg injected intravitreally once a month for two years when exudative AMD lesion is diagnosed to be active.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with classic, predominantly classic, minimally classic or occult type of exudative AMD and visual acuity at least 20/200.

Exclusion criteria

Prior treatment of exudative macular degeneration, prior intraocular surgery other than uncomplicated cataract surgery, uncomplicated cataract surgery within one year, diabetes, intraocular tumors, other retinal diseases or retinal vascular occlusions, prior retinal panphotocoagulation, prior significant intraocular inflammation or infection and poor co-operation.

Outcome results